CareFusion Corp (CFN)
CFN (NYSE:Health Services)
$37.53
-0.54
-1.42%
Today's Range: 37.53 - 38.23 |
CFN Avg Daily Volume: 2,040,300
| Last Update: 06/19/13 - 4:01 PM EDT |
| Volume: 1,384,402 |
| YTD Performance: 33.21%
|
| Open: $38.00 |
| Previous Close: $38.07 |
| 52 Week Range: $23.93 -
$38.49 |
| Oustanding Shares: 219,809,208 |
| Market Cap: 8,341,759,444 |
6-Month Chart
TheStreet Ratings Grade for CFN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
7 |
7 |
7 |
7 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
6 |
6 |
6 |
6 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.93 |
1.93 |
1.93 |
1.93 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
-24.48 |
|
| Price Earnings Comparisons: |
| CFN |
Sector Avg. |
S&P 500 |
| -24.48 |
22.60 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
12.20%
|
53.14%
|
54.25%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
2.00 |
-0.20 |
-0.07 |
| Net Income |
20.10 |
-0.36 |
-0.14 |
| EPS |
20.40 |
0.00 |
0.00 |
| Earnings for CFN: |
| EBITDA |
0.81B |
| Revenue |
3.60B |
|
Average Earnings Estimates
;Qtr (09/13);FY (06/13);FY (06/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (06/12);FY (06/13)) |
|
| Average Estimate |
$0.56 |
$0.48 |
$2.13 |
$2.36 |
| Number of Analysts |
13 |
7 |
14 |
13 |
| High Estimate |
$0.59 |
$0.50 |
$2.16 |
$2.45 |
| Low Estimate |
$0.54 |
$0.45 |
$2.11 |
$2.30 |
| Prior Year |
$0.51 |
$n.a. |
$1.78 |
$2.13 |
| Growth Rate (Year over Year) |
9.95% |
n.a.% |
19.58% |
10.98% |
Sep 07, 2012 | 7:55 AM EDT
Coverage of CFN was started with a Buy rating, ThinkEquity said. $30 price target. Company can continue to deliver solid organic growth...
| Aug 10, 2012 | 3:05 PM EDT
Expect the medical instrument supplier to reach new 2012 highs in the near term.
May 24, 2012 | 7:49 AM EDT
CFN was upgraded from Outperform to Buy, Credit Suisse said. Expect strong 2013 guidance from management. $30 price target.
Feb 17, 2012 | 7:47 AM EST
CFN was upgraded from Market Perform to Outperform, Morgan Keegan said. $31 price target. Company can expand margins over the coming qu...
Feb 13, 2012 | 7:48 AM EST
CFN estimates were boosted through 2015, Goldman Sachs said. Company is buying back more stock. Neutral rating and new $26 price target...
Jan 05, 2012 | 8:00 AM EST
CFN was upgraded from Market Perform to Outperform, BMO Capital said. $30 price target. Company is leveraged to multiple healthcare gro...
Dec 14, 2011 | 6:47 AM EST
CFN was initiated with a Market Perform rating, Morgan Keegan said. $28 price target. Company can generate double-digit annual earnings...
Nov 09, 2011 | 7:55 AM EST
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Airgas, Amylin, and CareFusion.
